Kimball Partners With Novo Nordisk

Firestone Indy Lights driver Charlie Kimball has formed a partnership with Novo Nordisk, a world leader in diabetes care, with the goal of showing that with proper management, diabetes does not have to be a roadblock.

Charlie Kimball Credit: Shawn Payne/Indy Lights

"When I was diagnosed with type 1 diabetes just a year and a half ago, I knew I could not allow the disease to get in the way of me chasing my dream of being a race car driver," said Kimball, who uses Levemir, an insulin produced by Novo Nordisk to help manage his diabetes. "My goal is to win the Firestone Indy Lights title. With the combination of insulin and delivery devices, such as the Levemir FlexPen, I have learned that daily diabetes management and glucose control can be easily and successfully integrated into my busy life both on and off the track."

Kimball, who is the only American open-wheeled racing driver to talk publicly about his diabetes, has a history of breaking the mold. He made international history with a podium finish in the Formula 3 Euro Series in his first race after he was diagnosed with diabetes in 2007.

"Charlie is a role model for anyone who feels inhibited by diabetes as he continues to accomplish remarkable achievements with the disease," said Camille Lee, vice president of diabetes brand marketing, at Novo Nordisk. "He proves that with today's treatment options, diabetes can be managed even in the most challenging circumstances."

Kimball has committed to working closely with his doctor, utilizing a regimen which includes Levemir FlexPen, an up to 24-hour long-acting basal insulin administered in a prefilled pen; and NovoLog, a rapid-acting insulin that can be taken 5-10 minutes before a meal, to help manage his blood glucose levels.

He checks his blood sugar regularly and keeps orange juice in his race car for easy access, in case his sugar levels are low while racing.

Print This Page	Go back to the previous page